Personal tools

Coexpression cluster:C395: Difference between revisions

From FANTOM5_SSTAR

Jump to: navigation, search
(Created page with "{{Coexpression_clusters |full_id=C395_Synoviocyte_Cardiac_Fibroblast_mesothelioma_Endothelial_Chondrocyte_tenocyte |id=C395 }}")
 
No edit summary
Line 2: Line 2:
|full_id=C395_Synoviocyte_Cardiac_Fibroblast_mesothelioma_Endothelial_Chondrocyte_tenocyte
|full_id=C395_Synoviocyte_Cardiac_Fibroblast_mesothelioma_Endothelial_Chondrocyte_tenocyte
|id=C395
|id=C395
|ontology_enrichment_celltype=CL:0000222!1.06e-27!119;CL:0000055!3.38e-18!180;CL:0000213!1.11e-16!57;CL:0000215!1.11e-16!57;CL:0000220!6.68e-16!246;CL:0002321!1.48e-15!248;CL:0002139!3.74e-15!24;CL:0002078!1.77e-12!44;CL:0000187!4.95e-12!54;CL:0000680!9.39e-12!57;CL:0000056!9.39e-12!57;CL:0000355!9.39e-12!57;CL:0000115!2.03e-11!35;CL:0000071!2.59e-11!18;CL:0002546!2.59e-11!18;CL:0000057!2.67e-11!75;CL:0000183!6.31e-11!59;CL:0000076!7.42e-11!62;CL:0000192!1.82e-10!42;CL:0000514!1.82e-10!42;CL:0000359!2.26e-10!32;CL:0000393!3.20e-10!60;CL:0000211!3.20e-10!60;CL:0002494!5.94e-08!16
|ontology_enrichment_disease=
|ontology_enrichment_uberon=UBERON:0000477!6.90e-30!286;UBERON:0004872!2.31e-29!84;UBERON:0002049!4.42e-28!79;UBERON:0007798!4.42e-28!79;UBERON:0000055!8.30e-26!69;UBERON:0004111!3.67e-25!241;UBERON:0000483!8.97e-24!309;UBERON:0001981!2.14e-23!60;UBERON:0007500!2.14e-23!60;UBERON:0004537!2.14e-23!60;UBERON:0006965!2.14e-23!60;UBERON:0000119!2.55e-23!312;UBERON:0003914!1.54e-22!118;UBERON:0001009!9.69e-22!113;UBERON:0004535!1.00e-21!110;UBERON:0000025!4.59e-20!194;UBERON:0000475!1.78e-18!365;UBERON:0000468!2.41e-18!659;UBERON:0001637!2.41e-17!42;UBERON:0003509!2.41e-17!42;UBERON:0004572!2.41e-17!42;UBERON:0000490!1.15e-16!138;UBERON:0000467!8.01e-15!625;UBERON:0000480!1.15e-14!626;UBERON:0000481!1.72e-14!347;UBERON:0004573!1.56e-13!33;UBERON:0004571!1.56e-13!33;UBERON:0006914!1.85e-11!25;UBERON:0001986!2.59e-11!18;UBERON:0004638!2.59e-11!18;UBERON:0004852!2.59e-11!18;UBERON:0002385!3.03e-11!63;UBERON:0001015!3.03e-11!63;UBERON:0000383!3.03e-11!63;UBERON:0001134!3.94e-11!61;UBERON:0002036!3.94e-11!61;UBERON:0003082!3.94e-11!61;UBERON:0000487!2.85e-10!22;UBERON:0000486!4.18e-10!82;UBERON:0002100!6.20e-10!216;UBERON:0005256!9.75e-10!143;UBERON:0000948!2.19e-09!24;UBERON:0005498!2.19e-09!24;UBERON:0004140!2.19e-09!24;UBERON:0009881!2.19e-09!24;UBERON:0004141!2.19e-09!24;UBERON:0003084!2.19e-09!24;UBERON:0007005!2.19e-09!24;UBERON:0004139!2.19e-09!24;UBERON:0004291!2.19e-09!24;UBERON:0000947!2.30e-09!21;UBERON:0010191!2.30e-09!21;UBERON:0007100!4.17e-09!27;UBERON:0004290!4.17e-09!70;UBERON:0000914!4.97e-09!83;UBERON:0002329!4.97e-09!83;UBERON:0003077!4.97e-09!83;UBERON:0003059!4.97e-09!83;UBERON:0007282!4.97e-09!83;UBERON:0009618!4.97e-09!83;UBERON:0007285!4.97e-09!83;UBERON:0000064!5.49e-08!219;UBERON:0002050!8.32e-08!605;UBERON:0005423!8.32e-08!605;UBERON:0000923!9.37e-08!604;UBERON:0005291!9.37e-08!604;UBERON:0006598!9.37e-08!604;UBERON:0002532!9.37e-08!604;UBERON:0000922!9.46e-08!612;UBERON:0003104!5.02e-07!238;UBERON:0009142!5.02e-07!238;UBERON:0003103!8.16e-07!69
}}
}}

Revision as of 14:42, 21 May 2012


Full id: C395_Synoviocyte_Cardiac_Fibroblast_mesothelioma_Endothelial_Chondrocyte_tenocyte



Phase1 CAGE Peaks

Hg19::chr2:56094041..56094058,-p@chr2:56094041..56094058
-
Hg19::chr2:56094202..56094227,-p@chr2:56094202..56094227
-
Hg19::chr2:56098185..56098199,-p@chr2:56098185..56098199
-
Hg19::chr2:56102125..56102145,-p@chr2:56102125..56102145
-
Hg19::chr2:56102173..56102210,-p@chr2:56102173..56102210
-
Hg19::chr2:56103806..56103824,-p@chr2:56103806..56103824
-
Hg19::chr2:56104899..56104948,-p@chr2:56104899..56104948
-
Hg19::chr2:56104927..56104972,+p@chr2:56104927..56104972
+
Hg19::chr2:56104951..56104962,-p@chr2:56104951..56104962
-
Hg19::chr2:56104999..56105010,-p@chr2:56104999..56105010
-
Hg19::chr2:56108781..56108808,-p@chr2:56108781..56108808
-
Hg19::chr2:56108835..56108875,-p@chr2:56108835..56108875
-
Hg19::chr2:56144804..56144841,+p@chr2:56144804..56144841
+
Hg19::chr2:56144851..56144902,-p@chr2:56144851..56144902
-
Hg19::chr2:56144905..56144921,-p@chr2:56144905..56144921
-
Hg19::chr2:56144922..56144937,+p@chr2:56144922..56144937
+
Hg19::chr2:56144928..56144943,-p@chr2:56144928..56144943
-
Hg19::chr2:56144945..56144975,-p@chr2:56144945..56144975
-
Hg19::chr2:56145005..56145022,-p@chr2:56145005..56145022
-
Hg19::chr2:56145014..56145064,+p@chr2:56145014..56145064
+
Hg19::chr2:56145124..56145158,+p@chr2:56145124..56145158
+
Hg19::chr2:56145348..56145379,+p@chr2:56145348..56145379
+
Hg19::chr2:56149625..56149641,-p11@EFEMP1
Hg19::chr2:56149661..56149678,-p10@EFEMP1
Hg19::chr2:56150184..56150209,-p6@EFEMP1
Hg19::chr2:56150883..56150896,-p2@EFEMP1
Hg19::chr2:56150910..56150938,-p1@EFEMP1


Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data


No results for this coexpression

Enriched Gene Ontology terms on this co-expression cluster<b>Summary:</b> Results for GOStat analysis on co-expressed clusters. Each cluster with promoters mapping to at least two different genes was analysed with GOStat (PMID: 14962934) with default parameter. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br>data


No GOStat results

Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br>cell_data<br>uberon_data<br><br>


Uber Anatomy
Ontology termp-valuen
anatomical cluster6.90e-30286
splanchnic layer of lateral plate mesoderm2.31e-2984
vasculature4.42e-2879
vascular system4.42e-2879
vessel8.30e-2669
anatomical conduit3.67e-25241
epithelium8.97e-24309
blood vessel2.14e-2360
epithelial tube open at both ends2.14e-2360
blood vasculature2.14e-2360
vascular cord2.14e-2360
cell layer2.55e-23312
epithelial tube1.54e-22118
circulatory system9.69e-22113
cardiovascular system1.00e-21110
tube4.59e-20194
organism subdivision1.78e-18365
multi-cellular organism2.41e-18659
artery2.41e-1742
arterial blood vessel2.41e-1742
arterial system2.41e-1742
unilaminar epithelium1.15e-16138
anatomical system8.01e-15625
anatomical group1.15e-14626
multi-tissue structure1.72e-14347
systemic artery1.56e-1333
systemic arterial system1.56e-1333
squamous epithelium1.85e-1125
endothelium2.59e-1118
blood vessel endothelium2.59e-1118
cardiovascular system endothelium2.59e-1118
muscle tissue3.03e-1163
musculature3.03e-1163
musculature of body3.03e-1163
skeletal muscle tissue3.94e-1161
striated muscle tissue3.94e-1161
myotome3.94e-1161
simple squamous epithelium2.85e-1022
multilaminar epithelium4.18e-1082
trunk6.20e-10216
trunk mesenchyme9.75e-10143
heart2.19e-0924
primitive heart tube2.19e-0924
primary heart field2.19e-0924
anterior lateral plate mesoderm2.19e-0924
heart tube2.19e-0924
heart primordium2.19e-0924
cardiac mesoderm2.19e-0924
cardiogenic plate2.19e-0924
heart rudiment2.19e-0924
aorta2.30e-0921
aortic system2.30e-0921
primary circulatory organ4.17e-0927
dermomyotome4.17e-0970
somite4.97e-0983
paraxial mesoderm4.97e-0983
presomitic mesoderm4.97e-0983
presumptive segmental plate4.97e-0983
trunk paraxial mesoderm4.97e-0983
presumptive paraxial mesoderm4.97e-0983
organ part5.49e-08219
embryonic structure8.32e-08605
developing anatomical structure8.32e-08605
germ layer9.37e-08604
embryonic tissue9.37e-08604
presumptive structure9.37e-08604
epiblast (generic)9.37e-08604
embryo9.46e-08612
mesenchyme5.02e-07238
entire embryonic mesenchyme5.02e-07238
compound organ8.16e-0769


Overrepresented TFBS (DNA) motifs on this co-expression cluster<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data


Novel motifs



JASPAR motifs

Motifs-log10(p-value)

{{{tfbs_overrepresentation_jaspar}}}



ENCODE TF ChIP-seq peak enrichment analysis<b>Summary:</b> For each TF and each co-expression cluster, the number of promoters with ENCODE TF ChIP signal was compared with the rest of promoters from the robust set using Fisher's exact test. Clusters with significant ChIP enrichment (q <= 0.05) after Benjamini-Hochberg correction were retained. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br><br>data


No analysis results for this cluster

Relative expression of the co-expression cluster<b>Summary:</b>Co-expression clusters are compared against FANTOM5 samples to obtain relative expression. <br><b>Analyst:</b>NA<br><br>link to data source<br> data


This analysis result is provided for C0 - C305 clusters.